Sevelamer
- Generic Name
- Sevelamer
- Brand Names
- Renagel, Renvela, Sevelamer carbonate Winthrop (previously Sevelamer carbonate Zentiva)
- Drug Type
- Small Molecule
- Chemical Formula
- C6H12ClNO
- CAS Number
- 52757-95-6
- Unique Ingredient Identifier
- 941N5DUU5C
- Background
Sevelamer is a phosphate binding drug used to prevent hyperphosphataemia in patients with chronic renal failure. It is marketed by Genzyme under the trade name Renagel.
- Indication
For the control of serum phosphorus in patients with Chronic Kidney Disease (CKD) on hemodialysis.
- Associated Conditions
- Hyperphosphataemia
Evaluate the Efficacy and Safety of JMKX003002 in End-Stage Renal Disease Patients on Hemodialysis with Hyperphosphatemia
- Conditions
- Hyperphosphatemia
- Interventions
- Drug: JMKX003002 will be administered orally
- First Posted Date
- 2024-10-29
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Jemincare
- Target Recruit Count
- 50
- Registration Number
- NCT06664125
- Locations
- 🇨🇳
The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
Calcium-Phosphorus Regulation Therapy on Heart Valve Disease
- Conditions
- Degenerative Heart Valve DiseaseHeart Valve CalcificationChronic Kidney Disease(CKD)Calcium-Phosphorus Metabolism Disorders
- Interventions
- First Posted Date
- 2024-10-28
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- China National Center for Cardiovascular Diseases
- Target Recruit Count
- 196
- Registration Number
- NCT06660524
- Locations
- 🇨🇳
Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Science, Beijing, Beijing, China
A Study to Evaluate Safety and Efficacy of AP-306 in Hyperphosphatemia Patients
- Conditions
- Chronic Kidney DiseasesHyperphosphatemia
- Interventions
- First Posted Date
- 2023-03-10
- Last Posted Date
- 2024-01-10
- Lead Sponsor
- Alebund Pharmaceuticals
- Target Recruit Count
- 55
- Registration Number
- NCT05764590
- Locations
- 🇨🇳
Sichuan Provincial People's Hospital, Chengdu, Sichuan, China
A Phase 2 Study to Evaluate the Safety and Efficacy of VS-505(AP301) to Treat Hyperphosphatemia in Hemodialysis Patients
- First Posted Date
- 2020-09-16
- Last Posted Date
- 2022-10-18
- Lead Sponsor
- Shanghai Alebund Pharmaceuticals Limited
- Target Recruit Count
- 158
- Registration Number
- NCT04551300
- Locations
- 🇨🇳
Wuxi People's Hospital, Wuxi, Jiangsu, China
🇨🇳Peking University People's Hospital, Beijing, Beijing, China
🇨🇳Peking University Third Hospital, Beijing, Beijing, China
Drug-drug Interaction Study of TPOXX When Co-administered With Phosphate Binders
- Conditions
- Smallpox
- Interventions
- Drug: sucroferric oxyhydroxide chewable tablet
- First Posted Date
- 2020-07-24
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- SIGA Technologies
- Target Recruit Count
- 44
- Registration Number
- NCT04485039
- Locations
- 🇺🇸
PPD Phase I Clinic, Austin, Texas, United States
Ferric Citrate for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease Undergoing Hemodialysis
- Conditions
- ESRDHyperphosphatemiaEnd Stage Renal Disease
- Interventions
- Drug: Ferric citrate tablet
- First Posted Date
- 2020-07-07
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Sinomune Pharmaceutical Co., Ltd
- Target Recruit Count
- 239
- Registration Number
- NCT04456803
- Locations
- 🇨🇳
The second hospital of Dalian medical university, Dalian, China
🇨🇳The second people's hospital of Huaian, Huai'an, China
🇨🇳Zhuzhou Central Hospital, Zhuzhou, China
Study in Healthy Adult Subjects to Assess the Effect of Phosphate Binders on the Pharmacokinetics of a Single Dose of Vadadustat
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2020-03-09
- Last Posted Date
- 2020-10-08
- Lead Sponsor
- Akebia Therapeutics
- Target Recruit Count
- 54
- Registration Number
- NCT04299633
- Locations
- 🇨🇦
Research Site, Quebec, Canada
A Long-Term Study of Tenapanor Alone or in Combination With Sevelamer in Patients With CKD on Dialysis and HP
- Conditions
- HyperphosphatemiaEnd Stage Renal Disease
- Interventions
- First Posted Date
- 2019-06-18
- Last Posted Date
- 2023-03-29
- Lead Sponsor
- Ardelyx
- Target Recruit Count
- 172
- Registration Number
- NCT03988920
- Locations
- 🇺🇸
Ardelyx Site #509, Houston, California, United States
Ferric Citrate for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease Undergoing Hemodialysis
- Conditions
- ESRDHyperphosphatemiaEnd Stage Renal Disease
- Interventions
- First Posted Date
- 2019-06-13
- Last Posted Date
- 2021-03-10
- Lead Sponsor
- Panion & BF Biotech Inc.
- Target Recruit Count
- 240
- Registration Number
- NCT03984760
- Locations
- 🇨🇳
Meihekou Central Hospital, Meihekou, China
🇨🇳The Affiliated Hospital of Qingdao University, Qingdao, China
🇨🇳Shengjing Hospital of China Medical University, Shenyang, China
GLP-1-mediated Gluco-metabolic Effects of Bile Acid Sequestration
- First Posted Date
- 2018-11-13
- Last Posted Date
- 2021-10-13
- Lead Sponsor
- Steno Diabetes Center Copenhagen
- Target Recruit Count
- 17
- Registration Number
- NCT03739268
- Locations
- 🇩🇰
Steno Diabetes Center Copenhagen, Gentofte Hospital, Hellerup, Denmark
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.